Fox Run Management L.L.C. Grows Stake in Ultragenyx Pharmaceutical Inc (RARE)

Fox Run Management L.L.C. increased its stake in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 186.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,453 shares of the biopharmaceutical company’s stock after purchasing an additional 7,453 shares during the quarter. Fox Run Management L.L.C.’s holdings in Ultragenyx Pharmaceutical were worth $531,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of RARE. Schwab Charles Investment Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 3.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 219,415 shares of the biopharmaceutical company’s stock valued at $13,628,000 after purchasing an additional 7,618 shares during the period. Legal & General Group Plc increased its holdings in shares of Ultragenyx Pharmaceutical by 17.2% in the second quarter. Legal & General Group Plc now owns 15,082 shares of the biopharmaceutical company’s stock valued at $933,000 after purchasing an additional 2,212 shares during the period. Prudential Financial Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 85.0% in the second quarter. Prudential Financial Inc. now owns 6,770 shares of the biopharmaceutical company’s stock valued at $420,000 after purchasing an additional 3,110 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 1.0% in the second quarter. Principal Financial Group Inc. now owns 73,412 shares of the biopharmaceutical company’s stock valued at $4,559,000 after purchasing an additional 722 shares during the period. Finally, Teachers Advisors LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 3.7% in the second quarter. Teachers Advisors LLC now owns 169,886 shares of the biopharmaceutical company’s stock valued at $10,552,000 after purchasing an additional 5,988 shares during the period. Hedge funds and other institutional investors own 83.83% of the company’s stock.

Shares of Ultragenyx Pharmaceutical Inc (NASDAQ RARE) traded up $2.98 on Wednesday, reaching $47.63. The company’s stock had a trading volume of 491,397 shares, compared to its average volume of 675,042. Ultragenyx Pharmaceutical Inc has a one year low of $41.67 and a one year high of $91.35. The firm has a market capitalization of $2,080.28, a price-to-earnings ratio of -6.83 and a beta of 1.89.

A number of research analysts have recently weighed in on the company. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. BidaskClub lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Canaccord Genuity set a $80.00 price objective on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, December 5th. Barclays raised their target price on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 5th. Finally, Robert W. Baird dropped their target price on Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $72.06.

ILLEGAL ACTIVITY NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/ultragenyx-pharmaceutical-inc-rare-stake-raised-by-fox-run-management-l-l-c.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply